- Innocan Pharma (INNO) announced positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform
- Six dogs suffering from osteoarthritis and lameness were administered a single subcutaneous injection of liposomal CBD
- Six weeks following the injection, owners reported that the dogs’ pain and well-being scores were improved
- The results show that the LPT technology has the potential to provide additional analgesia in dogs suffering from pain
- These experiments have demonstrated initial positive results, supporting Innocan’s intention to make CBD available to humans and animals
- Innocan is a pharmaceutical tech company
- InnoCan Pharma Corporation (INNO) opened trading at $0.51 per share
Innocan Pharma (INNO) announced positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform.
Six dogs suffering from osteoarthritis and lameness that were treated with oral analgesics but were still experiencing pain were administered a single subcutaneous injection of liposomal CBD in addition to their routine analgesics. CBD concentrations were observed for six weeks following the liposomal CBD injection in the dogs’ plasma. Owners reported that the dogs’ pain and well-being scores were improved for several weeks after the injection.
The results show that the LPT technology has the potential to provide additional analgesia in dogs suffering from pain.
On August 11, 2022, Innocan reported the first results from a study in dogs that showed close to 100 per cent bioavailability of CBD using Innocan’s LPT technology, compared to 6.5-20 per cent bioavailability in humans when administered orally.
Professor Chezy Barenholz of The Hebrew University commented on the initial success.
“The challenge to demonstrate significant efficacy is the core obstacle in CBD. We are proud to report that we are rising to this challenge. Our R&D team works tirelessly and we hope there will be disclosure of more results soon.”
Innocan CEO, Iris Bincovich added,
“Innocan is pleased to report today another important milestone that we achieved on the way to market. We will learn the results to its fullest and will provide updates and reports to the public when completed. These are exciting times for me and for Innocan, as we get to see our vision being manifested into clinical reality.”
By administering injectable CBD encapsulated in liposomes (the LPT platform), Innocan seeks to achieve long-lasting and therapeutic levels of CBD in the body.
Innocan carried out a series of experiments with its LPT platform on animals. These experiments have demonstrated initial positive results, supporting the viability of Innocan’s intention to make CBD available to humans and animals for extended periods upon a single injection. Innocan’s unique delivery method allows for the prolonged release of CBD into the bloodstream with improved pharmacokinetic (PK) performance.
The research is conducted in collaboration with the Hebrew University of Jerusalem and indicates potential for the company’s technology to deliver cannabinoids to the blood stream in a more effective manner.
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness.
InnoCan Pharma Corporation (INNO) opened trading at $0.51 per share.